Back to search
CD20-positive Hematological Malignancies
Clinical trial pipeline · Data from ClinicalTrials.gov
See which CD20-positive Hematological Malignancies trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which CD20-positive Hematological Malignancies trials you may qualify forThe aim of this study is to evaluate the pharmacokinetic characteristics, safety and efficacy of the TQB2825 injection (subcutaneous administration) in patients…
This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with rituximab in participants with CD20-positive lymphoproliferative disor…
This study will evaluate the safety and efficacy of 1A46 in adult patients with advanced CD20 and/or CD19 positive B-cell non-Hodgkin's lymphoma (NHL) or acute…
The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the…
This is a single-group, open, dose escalation and expansion Phase I clinical study, with phase I being a dose escalation study and Phase II being a dose expansi…
This phase II trial studies the side effects and best dose of bortezomib when given with chemotherapy and to see how well they work in treating participants wit…